Abstract
Drug-eluting stents (DES) have a significantly reduced in-stent restenosis (ISR). However, there is concern about the durability of the efficacy, i.e., late “catch-up” phenomenon [1,2]. In the bare-metal stent (BMS) era, the ISR occurred predominantly within the first year, which was clinically much more important than late restenosis. However, in the first generation DES era, late ISR leading to late target-lesion revascularization (TLR) beyond 1year has emerged as a new problem. The mechanisms of the late restenosis after the first-generation DES implantation are not fully understood.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.